HOME >> MEDICINE >> NEWS
Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy

Late-breaking presentation shows multilineage blood cell growth with excellent safety in chemotherapy patients

Maret Pharmaceuticals, Inc. today reported positive Phase I/II clinical results that demonstrate the potential of MARstem™ as a multilineage hematopoietic therapy (multiple blood cell stimulant) to treat or prevent pancytopenia (a reduction in different types of blood cells) following chemotherapy in breast cancer patients. The study was selected as a late breaking abstract at the 11th National Cancer Institute - European Organization for Research and Treatment of Cancer - American Association for Cancer Research (NCI-EORTC-AACR) Symposium on New Drugs in Cancer Therapy.

The study was designed to evaluate safety, optimal dose and proof-of-principle efficacy of MARstem in adjuvant breast cancer patients. The results show that MARstem reduced the frequency of grade 2-4 thrombocytopenia (decrease in the number of blood platelets), grade 2-4 anemia (deficiency in red blood cells), and grade 3-4 lymphopenia (reduction in the number of lymphocytes) as compared to controls.

"These early clinical results suggest that MARstem may effective in improving or reducing the debilitating side effects of cancer treatment," said Terry Winters, Ph.D., Chairman and Chief Executive Officer of Maret Pharmaceuticals. MARstem has a clear therapeutic benefit as a multilineage hematopoietic factor as compared to traditional hematopoietic stimulants, which selectively increase only a single blood cell line. The trials outcome is promising, as the safety of MARstem has been established and the preliminary efficacy results are encouraging.

The studys results suggest that MARstem exhibits an excellent safety profile. There were no dose-limiting toxicities in the patients treated with MARstem. Specifically, there were no adverse cardiovascular or hematologic effects. The overall occurrence of side effects was lower in MARstem pa
'"/>

Contact: Heather Rosoff
hrosoff@fkhealth.com
617-761-6770
Feinstein Kean Healthcare
9-Nov-2000


Page: 1 2

Related medicine news :

1. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
2. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
3. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. Pharmaceuticals and personal care products
6. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
7. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
8. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
9. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting
10. American Academy of Neurology presents 57th Annual Meeting in Miami Beach
11. Hard choices: Pitt researcher presents findings on when to accept organ transplants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... 03, 2020 , ... The growing adoption of artificial intelligence ... Virtual Conference, a two-day virtual event for radiology professionals that will be hosted ... follow-up to AuntMinnie.com's successful virtual event in spring 2020, in which thousands of ...
(Date:9/1/2020)... ... September 01, 2020 , ... Board certified ... Glendale. While the office will be the first to bear her name, Dr. ... augmentation (Brazilian butt lift), as well as rhinoplasty, facial rejuvenation, and many more ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... Health Network (AHN), are joining biomedical engineers from Carnegie Mellon University (CMU) to ... for cardiac patients who have undergone open heart surgery. , The AGH/CMU team ...
(Date:8/31/2020)... ... 2020 , ... Genesis Chiropractic Software and Billing Network ... of its integrated, HIPAA compliant, telehealth solution, available to US-based clients immediately. With ... seconds. , According to the U.S. Department of Health & Human Services, ...
(Date:8/31/2020)... ... August 31, 2020 , ... In an effort to ... is donating 10 percent of each hotel room booked with a special new ... Chicagoland & Northwest Indiana (RMHC-CNI) , effective immediately. Donations will be applied to ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... , ... August 27, 2020 , ... The GHT ... of its fundraising initiative for Feeding San Diego with a press conference ... GHT Companies presents the final check of $5,000.00+ representing an overall donation result exceeding ...
(Date:8/26/2020)... , ... August 26, 2020 ... ... of Eurofins BioPharma Services, Laboratory Testing division, expands its technology footprint with ... of Flow Cytometry platforms available. With industry-leading biomarker solutions, complemented with traditional ...
(Date:8/26/2020)... N.D. (PRWEB) , ... August 26, 2020 , ... As ... familiar with the daily routine for preventing the Coronavirus. Wear a mask, keep your ... and fiber advocate Dr. Denis Burkitt said it best in 1977, “How much better ...
Breaking Medicine Technology:
Cached News: